Big pharma companies hit with FDA warning letters in drug ad clampdown
The US Food and Drug Administration (FDA) has followed up on its promise to clampdown on misleading and deceptive drug …
Post
-
-
EASD 2025: zimislecel infusion advances insulin independence in T1D
At the 2025 European Association for the Study of Diabetes (EASD) meeting in Vienna, investigators reported one-year outcomes from FORWARD, …
-
Solving global CDMO challenges: Indena and TCG GreenChem’s strategic-alliance
Contract development and manufacturing organisations (CDMOs) are facing mounting pressures to streamline production processes while adhering to increasingly stringent quality …
-
Eli Lilly picks Virginia for $5bn drug manufacturing plant
Eli Lilly has revealed the foremost plans from its new swathe of new drug manufacturing facilities it aims to build …
-
VarmX and CSL form alliance for blood coagulation treatment development
VarmX has established a partnership with CSL for the development of VMX-C001, designed to aid in restoring blood coagulation in …
-
GSK plans $30bn investment for R&D in US
GSK has announced an investment of $30bn in the US over the next five years for research and development (R&D) …
-
Reunion Neuroscience expands Series A to $133m after positive trial milestones
The success of Reunion Neuroscience’s lead psychedelic candidate in a postpartum depression (PPD) trial has provided a last minute boost …
-
European Society of Cardiology (ESC) Annual Meeting 2025
The European Society of Cardiology (ESC) Annual Meeting 2025, held from August 29 to September 1 in Madrid, Spain, showcased …
-
Novo Nordisk secures EMA approval for Rybelsus label update
Novo Nordisk has received the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) approval for the …
-
aTyr Pharma stock crashes on Phase III pulmonary sarcoidosis fail
aTyr Pharma shares plunged more than 80% after its Phase III trial in pulmonary sarcoidosis failed to meet its primary …
-
Cadrenal Therapeutics acquires eXIthera’s Factor XIa inhibitors
Cadrenal Therapeutics has acquired eXIthera Pharmaceuticals’ portfolio of Factor XIa inhibitors to expand its offerings in the anticoagulation market. Under the …
-
Novartis returns to Monte Rosa for second time in a year with $5.7bn deal
Novartis has ventured back to Monte Rosa Therapeutics tasked with finding more immune-mediated disease drug candidates, signing a licensing deal …
-
Podcast: How RWD Furthers Understanding of Pregnancy
This podcast explores how real-world data (RWD) fills gaps in understanding maternal and infant health, especially since pregnant individual often …
-
AstraZeneca halts £200m research investment in Cambridge
AstraZeneca has halted its planned £200m ($270m) investment in a research facility in Cambridge, UK, according to reports from Reuters. The …
-
FDA chief blames decades of regulatory failure for misleading pharma ads
The US Food and Drug Administration (FDA) commissioner Martin Makary has described the current state of direct-to-consumer pharmaceutical advertising as …
